Antonio Raffone1, Jacopo Troisi2,3,4, Dominga Boccia1, Antonio Travaglino5, Giovanfrancesco Capuano1, Luigi Insabato5, Antonio Mollo2, Maurizio Guida1, Fulvio Zullo1. 1. Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy. 2. Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana", Neuroscience Section, University of Salerno, Baronissi, Italy. 3. Theoreo srl, Montecorvino Pugliano, Italy. 4. European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy. 5. Anatomic Pathology Unit, Department of Advanced Biomedical Sciences, School of Medicine, University of Naples Federico II, Naples, Italy.
Abstract
INTRODUCTION: Endometrial cancer (EC) is the most common gynecological malignancy in the developed world. The prognosis of EC strongly depends on tumor stage, hence the importance of improving diagnosis. Metabolomics has recently appeared as a promising test for a non-invasive diagnosis of several diseases. Nevertheless, no metabolic marker has been approved for use in the routine practice. We aimed to provide an overview of metabolomics findings in the diagnosis of EC. MATERIAL AND METHODS: A systematic review was performed by searching 8 electronic databases from their inception to October 2019 for studies assessing metabolomics in EC diagnosis. Extracted data included characteristics of patients and EC, serum concentration of metabolites in women with and without EC and its association with EC diagnosis, tumor behavior and pathological characteristics. RESULTS: Six studies with 732 women (356 cases and 376 controls) were included. Several metabolites were found able to predict the presence of EC, tumor behavior (progression and recurrence) and pathological characteristics (histotype, myometrial invasion, lymph vascular space invasion). CONCLUSIONS: Metabolomics might be suitable for a non-invasive diagnosis and screening of EC, offering the possibility to predict tumor behavior and pathologic characteristics. Further studies are necessary to validate these results. This article is protected by copyright. All rights reserved.
INTRODUCTION:Endometrial cancer (EC) is the most common gynecological malignancy in the developed world. The prognosis of EC strongly depends on tumor stage, hence the importance of improving diagnosis. Metabolomics has recently appeared as a promising test for a non-invasive diagnosis of several diseases. Nevertheless, no metabolic marker has been approved for use in the routine practice. We aimed to provide an overview of metabolomics findings in the diagnosis of EC. MATERIAL AND METHODS: A systematic review was performed by searching 8 electronic databases from their inception to October 2019 for studies assessing metabolomics in EC diagnosis. Extracted data included characteristics of patients and EC, serum concentration of metabolites in women with and without EC and its association with EC diagnosis, tumor behavior and pathological characteristics. RESULTS: Six studies with 732 women (356 cases and 376 controls) were included. Several metabolites were found able to predict the presence of EC, tumor behavior (progression and recurrence) and pathological characteristics (histotype, myometrial invasion, lymph vascular space invasion). CONCLUSIONS: Metabolomics might be suitable for a non-invasive diagnosis and screening of EC, offering the possibility to predict tumor behavior and pathologic characteristics. Further studies are necessary to validate these results. This article is protected by copyright. All rights reserved.
Authors: Kelechi Njoku; Amy E Campbell; Bethany Geary; Michelle L MacKintosh; Abigail E Derbyshire; Sarah J Kitson; Vanitha N Sivalingam; Andrew Pierce; Anthony D Whetton; Emma J Crosbie Journal: Cancers (Basel) Date: 2021-02-10 Impact factor: 6.575
Authors: Nathalie Kliemann; Vivian Viallon; Neil Murphy; Rebecca J Beeken; Joseph A Rothwell; Sabina Rinaldi; Nada Assi; Eline H van Roekel; Julie A Schmidt; Kristin Benjaminsen Borch; Claudia Agnoli; Ann H Rosendahl; Hanna Sartor; José María Huerta; Anne Tjønneland; Jytte Halkjær; Bas Bueno-de-Mesquita; Audrey Gicquiau; David Achaintre; Krasimira Aleksandrova; Matthias B Schulze; Alicia K Heath; Konstantinos K Tsilidis; Giovanna Masala; Salvatore Panico; Rudolf Kaaks; Renée T Fortner; Bethany Van Guelpen; Laure Dossus; Augustin Scalbert; Hector C Keun; Ruth C Travis; Mazda Jenab; Mattias Johansson; Pietro Ferrari; Marc J Gunter Journal: BMC Med Date: 2021-04-30 Impact factor: 8.775
Authors: Diego Raimondo; Antonio Raffone; Antonio Travaglino; Manuela Maletta; Paolo Casadio; Marco Ambrosio; Anna Chiara Aru; Angela Santoro; Gian Franco Zannoni; Luigi Insabato; Antonio Mollo; Fulvio Zullo; Renato Seracchioli Journal: Int J Gynaecol Obstet Date: 2021-07-18 Impact factor: 4.447
Authors: Antonio Raffone; Antonio Travaglino; Diego Raimondo; Dominga Boccia; Martino Vetrella; Paolo Verrazzo; Marcello Granata; Paolo Casadio; Luigi Insabato; Antonio Mollo; Renato Seracchioli Journal: Int J Gynaecol Obstet Date: 2021-06-19 Impact factor: 4.447